07:00 , Mar 17, 2016 |  BC Innovations  |  Tools & Techniques

Gut re-action

A group of New York academics has developed a protocol to turn human pluripotent stem cells into gut neurons, and believes it could provide the first non-surgical treatment for Hirschsprung's disease - a rare disorder...
08:00 , Jan 28, 2016 |  BC Innovations  |  Product R&D

Hitchhiker's guide to the gut

Applied Molecular Transport LLC (AMT) believes it has cracked the problem of orally delivering therapeutic proteins that has been the bane of biologics from the outset. The company has co-opted a strategy and a molecule...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

J&J other, pharmaceuticals news

Johnson & Johnson launched the fourth incubator in its JLABS network, located in South San Francisco, and named the first 10 companies in residence. J&J said the incubator can accommodate up to 50 startups. Eight...
01:47 , Mar 4, 2015 |  BC Extra  |  Company News

J&J launches second Bay Area JLABS incubator

Johnson & Johnson (NYSE:JNJ) launched the fourth incubator in its JLABS network, located in South San Francisco, Calif., and named the first 10 companies in residence. J&J said the incubator can accommodate up to 50...
08:00 , Feb 2, 2015 |  BC Week In Review  |  Company News

Applied Molecular Transport, J&J deal

Applied Molecular Transport granted Johnson & Johnson’s Janssen Biotech Inc. unit exclusive, worldwide rights to an undisclosed preclinical oral candidate, which is in development to treat inflammatory bowel disease (IBD). Applied Molecular’s Transint technology allows...
01:39 , Jan 29, 2015 |  BC Extra  |  Company News

Applied Molecular Transport, Janssen strike IBD deal

Applied Molecular Transport LLC (South San Francisco, Calif.) granted the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exclusive worldwide rights to an undisclosed preclinical oral candidate to treat inflammatory bowel disease (IBD). AMT...